ニボルマブによる間質性肺炎発症後も有効性が維持されている転移性腎癌の一例

堤壮吾; 大久保陽一郎; 滝沢明利; 安井将人; 野口剛; 梅本晋; 加藤晃史; 岸田健

文献

J-GLOBAL ID：201902267337697019 整理番号：19A1250420

ニボルマブによる間質性肺炎発症後も有効性が維持されている転移性腎癌の一例

A CASE OF METASTATIC KIDNEY CANCER FOR WHICH THE EFFICACY OF NIVOLUMAB THERAPY WAS MAINTAINED EVEN AFTER THE DEVELOPMENT OF INTERSTITIAL PNEUMONIA

出版者サイト {{ this.onShowPLink() }} 複写サービスで全文入手 {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=19A1250420&COPY=1") }}
高度な検索・分析はJDreamⅢで {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1250420&from=J-GLOBAL&jstjournalNo=U1099A") }}

著者 (8件)： , , , , , , ,
資料名：
巻： 110 号： 2 ページ： 124-128 (WEB ONLY) 発行年： 2019年
JST資料番号： U1099A ISSN： 1884-7110 資料種別：逐次刊行物 (A)
記事区分：原著論文発行国：日本 (JPN) 言語：日本語 (JA)

症例は52歳男性.腎癌に対し腹腔鏡下根治的左腎摘除術施行.術...

,...
,...

続きはJDreamIII（有料）にて {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1250420&from=J-GLOBAL&jstjournalNo=U1099A") }}

泌尿生殖器の腫よう , 腫ようの薬物療法 , 呼吸器の腫よう

引用文献 (11件)：

1) 小野薬品工業: オプジーボ適正使用ガイド. 2016.
2) Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF and Hodi FS: PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res., 22 (24), 6051-6060, 2016.
3) McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA and Atkins MB: Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol., 33 (18), 2013-2020, 2015.
4) McKay RR, Martini D, Moreira RB, Hamieh L, Norton C, Mullane SA, Walsh MK, Michaelson D, McDermott DF and VanAllen E: Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol., 2017.
5) Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wingginton JM, Hellmann MD, Kollia GD, Gupta AK and Brahmer JR: Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol., 3 (18), 2004-2012, 2015.

, , ,

前のページに戻る